Literature DB >> 28987492

Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.

Luca Fania1, Adele Salemme2, Alessia Provini2, Gianluca Pagnanelli2, Maria Chiara Collina2, Damiano Abeni2, Biagio Didona2, Giovanni Di Zenzo2, Cinzia Mazzanti2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28987492     DOI： 10.1016/j.jaad.2017.09.051

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  10 in total

1.  Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.

Authors:  Khalaf Kridin; Orly Avni; Giovanni Damiani; Dana Tzur Bitan; Erez Onn; Orly Weinstein; Arnon D Cohen
Journal:  Arch Dermatol Res       Date:  2022-01-15       Impact factor: 3.017

Review 2.  A Review of the Immunologic Pathways Involved in Bullous Pemphigoid and Novel Therapeutic Targets.

Authors:  Mohsen Afarideh; Robert Borucki; Victoria P Werth
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

3.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

4.  Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.

Authors:  Olivier Gaudin; Vannina Seta; Marina Alexandre; Gérôme Bohelay; Françoise Aucouturier; Sabine Mignot-Grootenboer; Saskia Ingen-Housz-Oro; Céline Bernardeschi; Pierre Schneider; Benoît Mellottee; Frédéric Caux; Catherine Prost-Squarcioni
Journal:  Front Immunol       Date:  2018-05-24       Impact factor: 7.561

Review 5.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

Review 6.  Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.

Authors:  Karim Chouchane; Giovanni Di Zenzo; Dario Pitocco; Laura Calabrese; Clara De Simone
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

7.  A case of bullous pemphigoid induced by torsemide.

Authors:  Paul Wurtz; Robert Borucki; Corey Georgesen
Journal:  JAAD Case Rep       Date:  2022-07-03

Review 8.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10

9.  More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Ralf J Ludwig; Khalaf Kridin; Sascha Ständer; Enno Schmidt; Detlef Zillikens
Journal:  Am J Clin Dermatol       Date:  2021-01       Impact factor: 7.403

10.  Serum autoantibodies against the extracellular region of α6β4 integrin in a patient with dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid.

Authors:  Chigusa Yamashita; Noriko Arase; Shuhei Higuchi; Hisashi Arase; Junichi Takagi; Satoshi Nojima; Atsushi Tanemura; Manabu Fujimoto
Journal:  JAAD Case Rep       Date:  2021-12-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.